Grant McKenzie, MD
Radiation Oncology · Winston Salem, NCNPI 1134651599
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,213 of the $3,973 with a category attached, or 80.9%. 28 manufacturers reported payments, led by Palette Life Sciences, Inc. at 27.2% of the total. Reporting peaked in 2023 at $1,527 and has fallen 91.1% since, to $136 in 2025.
Across 78 payments — averaging $50.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Palette Life Sciences, Inc.$1K
- Novocure Inc.$740
- GT Medical Technologies, Inc$358
- AstraZeneca$327
- Coherus Oncology, Inc.$246
- Merck$239
- plus $984 from 22 others
What the payments were for
- Travel & lodging$75919%
- Food & beverage$3,21381%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Palette Life Sciences, Inc. | 4 | $1,080 |
| Novocure Inc. | 14 | $740 |
| GT Medical Technologies, Inc | 3 | $358 |
| AstraZeneca | 7 | $327 |
| Coherus Oncology, Inc. | 2 | $246 |
| Merck | 12 | $239 |
| Boston Scientific | 2 | $149 |
| Monteris Medical Corporation | 1 | $130 |
| Alcresta Therapeutics, Inc. | 1 | $125 |
| Incyte Corporation | 6 | $111 |
| Azurity Pharmaceuticals, Inc. | 5 | $78 |
| Bayer | 3 | $51 |
| Stemline Therapeutics Inc. | 2 | $36 |
| Rigel Pharmaceuticals, Inc. | 2 | $30 |
| Johnson & Johnson | 1 | $29 |
| Arbor Pharmaceuticals, Inc. | 1 | $26 |
| Mirati Therapeutics, Inc. | 1 | $22 |
| Ambu Inc. | 1 | $21 |
| Seagen Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $21 |
| Foundation Medicine, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| G1 Therapeutics, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Sanofi | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune$391
- GammaTile$358
- IMFINZI$237
- Oncology$130
- Neuroblate$130
- RELIZORB$125
- GENERAL ONCOLOGY$123
- Udenyca$122
How this compares
$3,973 in reported general payments places this provider in the 85th percentile of 199 radiation oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 17 | $348 |
| Tamsulosin Hcl | 15 | $139 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Winston Salem
- Volker StieberWinston Salem$99K
- Michael ChanWinston Salem$32K
- Andrew FairchildWinston Salem$7K
- Doris BrownWinston Salem$3K
- Christina CramerWinston Salem$1K
- Andrew WangChapel Hill$118K
- Lewis SulmanDurham$54K
- Michael PapagikosWilmington$51K
- William LeeDurham$37K
- Matthew ManningGreensboro$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.